RiboX

Beyond's analysis on RiboX

• 2026-08-08 — RiboX Therapeutics secures FDA IND clearance for RXIM002, the world's first circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias, enabling Phase 1 trial initiation

Recent news mentioning RiboX

• 2026-08-08 — RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias

Appears alongside

• FDA
• IND
• CAR

Browse the full archive →